- $8.55bn
- $11.52bn
- $3.36bn
- 88
- 75
- 54
- 84
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,051 | 2,391 | 2,983 | 3,189 | 3,365 |
Cost of Revenue | |||||
Gross Profit | 1,524 | 1,759 | 2,146 | 2,231 | 2,413 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,402 | 1,627 | 2,573 | 2,670 | 2,448 |
Operating Profit | 649 | 764 | 411 | 519 | 917 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 532 | 631 | 256 | 377 | 777 |
Provision for Income Taxes | |||||
Net Income After Taxes | 517 | 588 | 276 | 362 | 651 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 454 | 162 | 278 | 362 | 652 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 454 | 162 | 278 | 366 | 664 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.02 | 2.01 | 1.85 | 1.24 | 2.26 |